AIxCrypto Holdings, Inc. — fact timeline

Campbell Becher was appointed as Director at AIxCrypto Holdings, Inc..

“On July 5, 2024, the Company’s Board of Directors appointed Campbell Becher, Robert Lim and Cody Price to serve as directors on the Board effective upon the Company’s receipt of the $2,000,000 pursuant to the Agreement.”

Ira Ritter resigned as Director at AIxCrypto Holdings, Inc..

“On July 5, 2024, Richard David, Sidney Emery, Kurt Kruger and Ira Ritter each resigned from his respective position as a member of the Company’s Board of Directors effective upon the Company’s receipt of the $2,000,000 pursuant to the Agreement.”

Kurt Kruger resigned as Director at AIxCrypto Holdings, Inc..

“On July 5, 2024, Richard David, Sidney Emery, Kurt Kruger and Ira Ritter each resigned from his respective position as a member of the Company’s Board of Directors effective upon the Company’s receipt of the $2,000,000 pursuant to the Agreement.”

Sidney Emery resigned as Director at AIxCrypto Holdings, Inc..

“On July 5, 2024, Richard David, Sidney Emery, Kurt Kruger and Ira Ritter each resigned from his respective position as a member of the Company’s Board of Directors effective upon the Company’s receipt of the $2,000,000 pursuant to the Agreement.”

Richard David resigned as Director at AIxCrypto Holdings, Inc..

“On July 5, 2024, Richard David, Sidney Emery, Kurt Kruger and Ira Ritter each resigned from his respective position as a member of the Company’s Board of Directors effective upon the Company’s receipt of the $2,000,000 pursuant to the Agreement.”

AIxCrypto Holdings, Inc. incurred convertible notes of $1,100,000 with Yi Hua Chen at 8% per annum maturing December 31, 2024.

“On April 12, 2024, against Chen’s Option exercise price of $1,000,000 paid to us, we delivered to Chen: - an 8% Convertible Debenture (the “Chen Debenture”) in the principal amount of $1,100,000, of like tenor as the Alpha Debenture except for the principal amount”

AIxCrypto Holdings, Inc. terminated License and Sublicense Agreement with Pan-RAS Holdings, Inc. (effective 2024-03-25).

“On March 25, 2024, as of March 16, 2024, we entered into a Termination Agreement with Pan-RAS Holdings, Inc., a New York corporation (“ Pan-RAS Holdings ”). The Termination Agreement terminated, without liability on either party, the License and Sublicense Agreement dated February 15, 2024 between us and Pan-RAS Holdings (the “ License and Sublicense Agreement ”).”

AIxCrypto Holdings, Inc. entered into Securities Purchase Agreement with Alpha Capital Anstalt valued at $500,000 (effective 2024-02-26).

“On February 26, 2024, Qualigen Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (“Agreement”) with Alpha Capital Anstalt (“Alpha”). The transactions contemplated by the Agreement are expected to close on February 27, 2024, at which time the Company would deliver to Alpha the Debenture and the Warrant, as described below, and Alpha would pay the Company a cash purchase price of $500,000 (less expenses).”

Tariq Arshad resigned as Senior Vice President/Chief Medical Officer at AIxCrypto Holdings, Inc..

“On February 25, 2024, Tariq Arshad resigned from his position as the Company’s Senior Vice President/Chief Medical Officer.”

AIxCrypto Holdings, Inc. amended Amendment No. 1 with Alpha Capital Anstalt (effective 2023-12-05).

“On December 5, 2023, we entered into an Amendment No. 1 with regard to Securities Purchase Agreement, with Alpha Capital Anstalt.”

AIxCrypto Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 21, 2023, the Company also received a letter (the “Equity Deficiency Letter”) from Nasdaq notifying the Company that, based on the Company’s stockholders’ deficit of ($1,640,552) as of September 30, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2.5 million (the “Minimum Sto”

AIxCrypto Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 21, 2023, the Company also received a letter (the “Equity Deficiency Letter”) from Nasdaq notifying the Company that, based on the Company’s stockholders’ deficit of ($1,640,552) as of September 30, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2.5 million (the “Minimum Sto”

AIxCrypto Holdings, Inc. entered into Waiver with Alpha Capital Anstalt valued at $3,300,000 (effective 2023-09-22).

“On September 22, 2023, Qualigen Therapeutics, Inc. (the “Company”) entered into a consent and waiver (the “Waiver”) with Alpha Capital Anstalt (“Alpha”) with respect to the 8% Senior Convertible Debenture in the aggregate principal amount of $3,300,000 issued by the Company to Alpha on December 22, 2022 (the “Debenture”).”

AIxCrypto Holdings, Inc. reported the quarter ended June 30, 2023 results: revenue approximately $1.6 million.

“Revenues from product sales for the quarter ended June 30, 2023 were approximately $1.6 million compared to approximately $1.4 million for the same period of 2022”

AIxCrypto Holdings, Inc. completed a disposition involving Chembio Diagnostics, Inc. for $5.1 million in cash (closed 2023-07-20).

“the consummation of the Transaction, the Subsidiary became a wholly-owned subsidiary of the Buyer. The aggregate net purchase price paid to the Company for the Shares was $5.1 million in cash, based on a base purchase price of $5.8 million, subject to certain post-closing adjustments, upward or downward, as applicable, for: (i) cash held by the Subsidiary as”

AIxCrypto Holdings, Inc. amended Nanosynex Amendment with Nanosynex Ltd. valued at aggregate amount of $1,610,000 (effective 2023-07-20).

“On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with Nanosynex Ltd. (the “Nanosynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of Nanosynex Ltd. (“Nanosynex”), dated May 26, 2022, by and between the Company and Nanosynex (the “Original Nanosynex Agreement”), a majority owned subsidiary of the Company, to, among other things, provide for the further funding of Nanosynex, as contemplated by the Original Nanosynex Agreement.”

AIxCrypto Holdings, Inc. entered into Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A. valued at $5.1 million in cash, based on a base purchase price of $5.8 million (effective 2023-07-20).

“On July 20, 2023, Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a stock purchase agreement (the “Purchase Agreement”) with Chembio Diagnostics, Inc. (the “Buyer”), Biosynex, S.A. (“Biosynex”), and Qualigen, Inc., a wholly-owned subsidiary of the Company (the “Subsidiary”).”

AIxCrypto Holdings, Inc. shareholders approved Proposal to approve, on a non-binding, advisory basis, the compensation of our named executive officers at the 2023-07-13 meeting.

“4. Proposal to approve, on a non-binding, advisory basis, the compensation of our named executive officers: Votes Abstaining Broker Non-Votes 477,848 206,074 16,203 1,594,197 The proposal was approved.”

AIxCrypto Holdings, Inc. shareholders approved Proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance to Alpha Capital Anstalt (“Alpha”) of more than 20% of the Company’s issued and outstanding common stock pursuant to the terms and conditions of (a) the 8% Senior Convertible Debenture Due December 22, 2025 at the 2023-07-13 meeting.

“3. Proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance to Alpha Capital Anstalt (“Alpha”) of more than 20% of the Company’s issued and outstanding common stock pursuant to the terms and conditions of (a) the 8% Senior Convertible Debenture Due December 22, 2025 in favor of Alpha, and (b) the Company’s common stock purchase warrant dated December 22, 2022 issued to Alpha Votes Abstaining Broker Non-Votes 465,970 223,070 11,085 1,594,197 The proposal was approved.”

AIxCrypto Holdings, Inc. shareholders approved Proposal to ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-07-13 meeting.

“2. Proposal to ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023: Votes Abstaining 2,101,925 163,263 29,134 The proposal was approved.”

AIxCrypto Holdings, Inc. shareholders approved Election of Six Director Nominees at the 2023-07-13 meeting.

“1. Election of Six Director Nominees: Votes Withheld Broker Non-Votes Michael Poirier 501,410 198,715 1,594,197 Richard David 529,104 171,021 1,594,197 Sidney Emery, Jr. 503,712 196,413 1,594,197 Matthew Korenberg 513,635 186,490 1,594,197 Kurt Kruger 498,936 201,189 1,594,197 Ira Ritter 529,686 170,439 1,594,197 Each director nominee was elected to serve as a director until the Company’s annual meeting of stockholders in 2024, or until such person’s successor is duly elected and qualified or until such person’s earlier resignation, death, or removal.”

Amy Broidrick resigned as President, Chief Strategy and Operating Officer at AIxCrypto Holdings, Inc..

“Amy Broidrick, President, Chief Strategy and Operating Officer and a director of Qualigen Therapeutics, Inc. (the “Company”), provided her resignation to the Company, which became effective June 16, 2023”

Amy Broidrick resigned as President, Chief Strategy and Operating Officer and Director at AIxCrypto Holdings, Inc..

“On May 16, 2023, Amy Broidrick, President, Chief Strategy and Operating Officer and a director of Qualigen Therapeutics, Inc. (the “Company”), provided her resignation to the Company, which will become effective June 16, 2023 (the “Effective Date”).”

AIxCrypto Holdings, Inc. received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).

“May 4, 2023 that it had regained compliance with Nasdaq’s listing rule 5250(c)(1) as a result thereof and that the matter is now closed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: May 5, 2023 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer”

AIxCrypto Holdings, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 20, 2023, Qualigen Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Form 10-K”), the Company is no longer in compliance with the timely filing requirements for continued listing under Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”)”

Amy Broidrick changed role as President, Chief Strategy and Operating Officer at AIxCrypto Holdings, Inc..

“Ms. Broidrick’s title will become President, Chief Strategy and Operating Officer, effective as of the Effective Date.”

Shishir Sinha was terminated as Chief Operating Officer and Senior Vice President, Diagnostics at AIxCrypto Holdings, Inc..

“the Company provided notice to Mr. Sinha that his employment with the Company would be terminated effective February 16, 2023”

AIxCrypto Holdings, Inc. incurred convertible notes of $3,300,000 with Alpha Capital Anstalt at 8% per annum maturing December 22, 2025.

“Alpha Capital Anstalt (“Alpha”), pursuant to which it agreed to issue to Alpha, an 8% Senior Convertible Debenture (the “Debenture”) in the aggregate principal amount of $3,300,000 for a purchase price of $3,000,000. The Debenture will be convertible, at any time, and from time to time, at Alpha’s option, into shares of common stock of the Company (the”

AIxCrypto Holdings, Inc. entered into Securities Purchase Agreement with Alpha Capital Anstalt valued at $3,300,000 (effective 2022-12-21).

“On December 21, 2022, Qualigen Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (“Agreement”) with Alpha Capital Anstalt (“Alpha”), pursuant to which it agreed to issue to Alpha, an 8% Senior Convertible Debenture (the “Debenture”) in the aggregate principal amount of $3,300,000 for a purchase price of $3,000,000.”

AIxCrypto Holdings, Inc.: 公司提交了公司章程修正案以实施1比10的反向股票拆分 (effective 2022-11-23).

“On November 21, 2022, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding Common Stock, effective November 23, 2022 at 12:01 a.m., Eastern Time (the “Effective Time”).”

AIxCrypto Holdings, Inc. shareholders approved Approve an amendment to the certificate of incorporation to effect a reverse stock split of common stock at a ratio within 1-for-5 to 1-for-10 at the 2022-10-28 meeting.

“At the reconvened Annual Meeting, the stockholders approved Proposal 4 by the following votes: Votes For Votes Against Votes Abstaining 19,659,769 5,072,906 99,677”

Amy Broidrick was appointed as President/Chief Strategy Officer at AIxCrypto Holdings, Inc..

“On December 8, 2021, our Board appointed Amy Broidrick, who had been serving as our Executive Vice President/Chief Strategy Officer since December 2020, to the position of President/Chief Strategy Officer (effective December 10, 2021).”